149289-31-6

Basic information

• Product Name: 1-(4-METHOXYPHENYL)-2-AMINOETHYL CYCLOHEXANOL HYDROCHLORIDE
• Synonyms: 1-[2-AMINO-1-(4-METHOXYPHENYL)ETHYL]CYCLOHEXANOL HCL;2-(4-METHOXYPHENYL)-2-(1-HYDROXYCYCLOHEXYL)ETHYLAMINE HYDROCHLORIDE
• CAS NO: 149289-31-6
• Molecular Formula: C15H24ClNO2
• Molecular Weight: 285.81
• Mol File: 149289-31-6.mol

Chemical Properties

• Melting Point: 172-180°C
• Boiling Point: 394.608 °C at 760 mmHg
• Flash Point: 192.452 °C
• Appearance: /
• Density: 1.108 g/cm³
• CAS DataBase Reference: 1-(4-METHOXYPHENYL)-2-AMINOETHYL CYCLOHEXANOL HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-METHOXYPHENYL)-2-AMINOETHYL CYCLOHEXANOL HYDROCHLORIDE(149289-31-6)
• EPA Substance Registry System: 1-(4-METHOXYPHENYL)-2-AMINOETHYL CYCLOHEXANOL HYDROCHLORIDE(149289-31-6)

Safety Data

• Hazardous Substances Data: 149289-31-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-METHOXYPHENYL)-2-AMINOETHYL CYCLOHEXANOL HYDROCHLORIDE is used as a potential therapeutic agent for the treatment of psychiatric and neurological disorders due to its potential antidepressant, analgesic, and anti-inflammatory effects.
Used in Antidepressant Applications:
1-(4-METHOXYPHENYL)-2-AMINOETHYL CYCLOHEXANOL HYDROCHLORIDE is used as an antidepressant agent, as it has been studied for its potential to alleviate symptoms of depression by modulating the activity of certain neurotransmitters in the brain.
Used in Analgesic Applications:
1-(4-METHOXYPHENYL)-2-AMINOETHYL CYCLOHEXANOL HYDROCHLORIDE is used as an analgesic agent, as it has been studied for its potential to provide pain relief and manage chronic pain conditions.
Used in Anti-Inflammatory Applications:
1-(4-METHOXYPHENYL)-2-AMINOETHYL CYCLOHEXANOL HYDROCHLORIDE is used as an anti-inflammatory agent, as it has been studied for its potential to reduce inflammation and alleviate symptoms associated with inflammatory conditions.
Used in Substance Abuse Treatment:
1-(4-METHOXYPHENYL)-2-AMINOETHYL CYCLOHEXANOL HYDROCHLORIDE is used as a potential treatment for substance abuse disorders, as it has been investigated for its ability to modulate the activity of certain neurotransmitters in the brain, which may help in managing addiction and withdrawal symptoms.
However, it is important to note that further research is needed to fully understand the safety and efficacy of 1-(4-METHOXYPHENYL)-2-AMINOETHYL CYCLOHEXANOL HYDROCHLORIDE for clinical use.

Upstream product

• 108-94-1 cyclohexanone 
• 469905-08-6 2-(4-methoxy-phenyl)-1-oxa-spiro[2.5]octane-2-carbonitrile 
• 1336-21-6 ammonium hydroxide 
• 93413-76-4 1-[cyano(4-methoxyphenyl)methyl]cyclohexanol 
• 141-43-5 ethanolamine 
• 104-47-2 p-methoxybenzylnitrile 
• 131801-69-9 1-[Cyano(p-methoxyphenyl) methyl] cyclohexanol 
• 1204232-46-1 1-[2-amino-1-(4-methoxyphenyl)ethyl]cyclohexanol methanesulfonate salt 
• 130198-05-9 1-[2-amino-1-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride 
• 108-93-0 cyclohexanol 

Downstream Products

• 93413-90-2 N-Desmethylvenlafaxine hydrochloride 
• 149289-30-5 N-Desmethylvenlafaxine 
• 93413-69-5 1-[2-dimethylamino-1-(4-methoxyphenyl)ethyl]cyclohexanol 

Relevant articles and documents

Synthetic method of venlafaxine hydrochloride intermediate

The invention provides a synthetic method of a venlafaxine hydrochloride intermediate, the venlafaxine hydrochloride intermediate is a compound 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol as shown in a formula I. The method comprises the following steps: carrying out hydrogenation catalytic reaction on a compound 1-cyano-(4-methoxyphenyl) methyl cyclohexanol as shown in a formula II as a raw material; and carrying out hydrogenation catalytic reaction by adopting a copper-nickel catalyst to obtain the compound as shown in the formula I. The venlafaxine hydrochloride produced by the method can effectively control the generation of impurities, and the yield and the purity of the compound shown in the formula I are improved.

SUBSTITUTED ARYLUREA COMPOUNDS FOR INDUCING APOPTOSIS AND COMPOSITION FOR ANTICANCER COMPRISING THE SAME

The present invention relates to a substituted arylurea compound inducing apoptosis and an anticancer composition comprising the same. The present invention relates to a novel compound capable of preventing, treating and alleviating cancer diseases such as prostate cancer, breast cancer, lung cancer, colorectal cancer, and skin cancer by inhibiting apoptosis of cancer cells and inhibiting proliferation of cancer cells.

Preparation method of venlafaxine impurity E (by machine translation)

The invention belongs to the technical field of organic synthesis, and relates to a preparation method of venlafaxine impurity E, which comprises (1) a condensation reaction, (2) a reduction reaction and (3) a ring-forming reaction. The method for synthesizing venlafaxine impurity E is less in steps, high in product purity, safe in reaction, less in waste liquid, simple in post-treatment, convenient to operate and convenient for industrial production. (by machine translation)

A method for the preparation of venlafaxine hydrochloride (by machine translation)

The invention discloses a method for the preparation of venlafaxine hydrochloride. The method is provided with the screen of the Raney nickel catalyst in the micro-reactor, at a temperature of 20 - 40 °C lower, compound I with the hydrogen reaction to obtain compound II; compound II by adding sulfuric acid to form the salt to obtain the target product 1 - [2 - amino - 1 - (4 - methoxyphenyl) ethyl] cyclohexanol sulfate (compound III). The present invention provides a micro-reactor on the basis of the Raney nickel sieve catalyst of the creativity of the card in the pipe joint, the catalytic effect is enhanced, and the catalyst can be recycled, at the same time avoid the catalyst mixed in the feed liquid to the micro-reactor slurry pump damage and to avoid reaction of the pipeline blockage. (by machine translation)

Screening of quinoline, 1,3-benzoxazine, and 1,3-oxazine-based small molecules against isolated methionyl-tRNA synthetase and A549 and HCT116 cancer cells including an in silico binding mode analysis

Elevated activity of methionyl-tRNA synthetase (MRS) in many cancers renders it a possible drug target in this disease area, as well as in a series of parasitic diseases. In the present work, we report the synthesis and in vitro screening of a library of 1,3-oxazines, benzoxazines and quinoline scaffolds against human MRS. Among the compounds tested, 2-(2-butyl-4-chloro-1-(4-phenoxybenzyl)-1H-imidazol-5-yl)-5-(4-methoxyphenyl)-1-oxa-3-azaspiro[5.5]undecane (compound 21) and 2-(2-butyl-4-chloro-1-(4-nitrobenzyl)-1H-imidazol-5-yl)-2,4-dihydro-1H-benzo[d][1,3]oxazine (compound 8) were found to be potent inhibitors of MRS. Additionally, these compounds significantly suppressed the proliferation of A549 and HCT116 cells with IC50 values of 28.4, 17.7, 41.9, and 19.8 μM respectively. Molecular docking studies suggested that the ligand binding orientation overlaps with the original positions of both methionine and adenosine of MRS. This suggests the binding of compound 21 against MRS, which might lead the inhibitory activity towards cancer cells.

DERIVATIVES OF (-)-VENLAFAXINE AND METHODS OF PREPARING AND USING THE SAME

Methods of preparing, and compositions comprising, derivatives of (?)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.

An improved and impurity-free large-scale synthesis of venlafaxine hydrochloride

An improved and impurity-free synthetic method for large-scale synthesis of venlafaxine hydrochloride was developed using inexpensive reagents. The overall yield obtained from this newly developed process is 55% in a highly pure state with >99.9% purity by HPLC.

A PROCESS FOR PREPARATION OF PHENETHYLAMINE DERIVATIVE

The present invention relates to a process for the preparation of 1-[2-amino-1-(4-substituted phenyl)ethyl]cyclohexanol (3) (where R is OMe, OH), said process comprising the steps of; subjecting a reaction mixture of substituted phenylacetonitrile (2) in alcohol, an organic acid, and a hydrogenating catalyst in the presence of hydrogen gas pressure in the range of 0.5 kg/cm2 to 30 kg/cm2 and temperature in the range of 0-100°C; filtering and concentrating the cooled reaction mixture to obtain an acid addition salt of 1-[2-amino-1-(4-substituted phenyl)ethyl]cyclohexanol (4); and treating the acid addition salt of 1-[2-amino-1-(4-substituted phenyl)ethyl]cyclohexanol (4) with an ester in presence of a base to obtain 1-[2-amino-1-(4-substituted phenyl) ethyl] cyclohexanol (3).

PROCESS FOR THE PREPARATION OF PHENETHYLAMINE DERIVATIVES

The present invention relates to an improved process for the preparation of essentially pure Venlafaxine Hydrochloride. Particularly, the process for the preparation of Venlafaxine Hydrochloride comprises the following steps: i) Preparation of 1-[Cyano-1-(4-methoxyphenyl)methyl]cyclohexanol, ii) Preparation of crude Venlafaxine Hydrochloride by reduction of 1-[Cyano-1-(4-methoxyphenyl)methyl]cyclohexanol with Alkali metal borohydride and Lewis acid and subsequent conversion to Venalfaxine hydrochloride with formic acid and paraformaldehyde and finally iii) Purification of crude Venlafaxine Hydrochloride.

A PROCESS FOR THE PREPARATION OF VENLAFAXINE HYDROCHLORIDE

The present invention relates to a process for the preparation of Venlafaxine Hydrochloride comprising steps of i) treating 4-methoxyphenyl acetonitrile with cyclohexanone in presence of alkali hydroxide and super base to get 1-[cyano (4-methoxyphenyl) methyl] cyclohexanol and ii) reducing 1-[cyano (4-methoxyphenyl) methyl] cyclohexanol in presence of catalyst, activator and alcoholic ammonia under hydrogen pressure.